Product Description
This biosimilar antibody shares the same variable regions as Izalontamab, making it well suited for research applications. Izalontamab is a bispecific antibody combining a Human IgG1 with two ScFv that simultaneously targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), two receptor tyrosine kinases frequently overexpressed in solid tumors. EGFR and HER3 drive tumor cell proliferation, survival, and resistance to targeted therapies, and their co-engagement allows Izalontamab to overcome the compensatory signaling and resistance mechanisms that often limit single-target approaches. The therapeutic form of this antibody, Izalontamab brengitecan, is an antibody-drug conjugate (ADC) in which Izalontamab serves as the targeting moiety for a cytotoxic payload delivered to EGFR/HER3-expressing tumor cells. Izalontamab brengitecan has shown promising antitumor activity across multiple solid tumors, including non-small cell lung cancer, prostate cancer, and head and neck cancers. This biosimilar is provided as the unconjugated antibody, without the cytotoxic payload. It is intended for research use in studying EGFR/HER3 biology, bispecific antibody binding and signaling, dual receptor targeting strategies, and as a non-cytotoxic control for ADC studies in cancer models.
* VAT and shipping costs not included. Errors and price changes excepted
